Verastem Drug Patent Portfolio
Verastem owns 1 orange book drug protected by 7 US patents Given below is the list of Verastem's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11873296 | Solid forms of a dual RAF/MEK inhibitor | 29 Dec, 2042 | Active |
| US12509450 | Solid Forms Of A Dual Raf/Mek Inhibitor | 29 Dec, 2042 | Active |
| US11517573 | Therapeutic compositions, combinations, and methods of use | 11 Sep, 2040 | Active |
| US11400090 | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder | 29 Oct, 2038 | Active |
| US7928109 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | 21 Aug, 2029 | Active |
| US8247411 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | 17 Apr, 2028 | Active |
| US7897792 | Coumarin derivative having antitumor activity | 09 Feb, 2027 | Active |
Latest Legal Activities on Verastem's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Verastem.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Information Disclosure Statement considered | 14 Sep, 2025 | US12509450 |
| Printer Rush- No mailing | 14 Sep, 2025 | US12509450 |
| Pubs Case Remand to TC | 11 Sep, 2025 | US12509450 |
| Mail Notice of Allowance | 08 Sep, 2025 | US12509450 |
| Email Notification | 08 Sep, 2025 | US12509450 |
| Notice of Allowance Data Verification Completed | 05 Sep, 2025 | US12509450 |
| Information Disclosure Statement (IDS) Filed | 28 Aug, 2025 | US12509450 |
| Information Disclosure Statement considered | 25 Aug, 2025 | US12509450 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US7928109 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US11400090 |
| Information Disclosure Statement (IDS) Filed | 19 Aug, 2025 | US7928109 |
| Information Disclosure Statement (IDS) Filed | 19 Aug, 2025 | US11400090 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US11400090 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US7928109 |
| Information Disclosure Statement considered | 18 Jul, 2025 | US12509450 |
Verastem's Family Patents
Verastem Drug List
Given below is the complete list of Verastem's drugs and the patents protecting them.
1. Avmapki Fakzynja Co-pack (copackaged)
Avmapki Fakzynja Co-pack (copackaged) is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11873296 | Solid forms of a dual RAF/MEK inhibitor |
29 Dec, 2042
(16 years from now)
| Active |
| US12509450 | Solid Forms Of A Dual Raf/Mek Inhibitor |
29 Dec, 2042
(16 years from now)
| Active |
| US11517573 | Therapeutic compositions, combinations, and methods of use |
11 Sep, 2040
(14 years from now)
| Active |
| US11400090 | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder |
29 Oct, 2038
(12 years from now)
| Active |
| US7928109 | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
21 Aug, 2029
(3 years from now)
| Active |
| US8247411 | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
17 Apr, 2028
(2 years from now)
| Active |
| US7897792 | Coumarin derivative having antitumor activity |
09 Feb, 2027
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avmapki Fakzynja Co-pack (copackaged)'s drug page